02 March 2026
02 March 2026
Article doesn't exist
2025 was a record year for Boehringer in terms of licensing deals, with a majority of these agreements being oncology or immunology-focused.
Before eyeing a Nasdaq ticker, AI drug discovery specialist Generate already attracted interest from Amgen and Novartis.
Yuviwel’s approval marks a more convenient option compared to BioMarin’s daily injection Voxzogo.
The approval follows PEGASUS Phase III trial assessing Palynziq efficacy and safety compared to diet alone in adolescents with PKU.
The CHMP’s recommendation is based on LIBERTY-CUPID data, including two Phase III and the CUPIDKids studies.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
